97628-92-7

Basic information

• Product Name: 1-(BENZYLOXYCARBONYL) AZETIDINE-3-CARBOXYLIC ACID
• Synonyms: 1-(BENZYLOXYCARBONYL) AZETIDINE-3-CARBOXYLIC ACID;1-Cbz-azetidine-3-carboxylic acid;N-Cbz-azetidine-3-carboxylic acid;1-benzyloxycarbonyl-3-azetidinecarboxylic acid;1-Cbz-azetidine-3-carboxy...;CBZ-AZETIDINE-3-CARBOXYLIC ACID;N-(Benzyloxycarbonyl)azetidine-3-carboxylic acid, 95%;Azetidine-1,3-dicarboxylic acid 1-benzyl ester
• CAS NO: 97628-92-7
• Molecular Formula: C₁₂H₁₃NO₄
• Molecular Weight: 235.23592
• Mol File: 97628-92-7.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 421.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.362
• Storage Temp.: 2-8°C
• PKA: 4.19±0.20(Predicted)
• CAS DataBase Reference: 1-(BENZYLOXYCARBONYL) AZETIDINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(BENZYLOXYCARBONYL) AZETIDINE-3-CARBOXYLIC ACID(97628-92-7)
• EPA Substance Registry System: 1-(BENZYLOXYCARBONYL) AZETIDINE-3-CARBOXYLIC ACID(97628-92-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 97628-92-7(Hazardous Substances Data)

Usage

General Description

1-(Benzyloxycarbonyl)azetidine-3-carboxylic acid is a chemical compound with the molecular formula C13H15NO4. It is a derivative of azetidine, which is a four-membered ring containing nitrogen. The compound contains a benzyl functional group and a carboxylic acid group. It is used in organic synthesis as a building block for the preparation of other compounds. It has been studied for its potential pharmacological properties, including its use as an antibacterial agent and as a component in the preparation of pharmaceutical compounds. Its chemical structure and properties make it a valuable tool for researchers and chemists in the field of drug development and organic chemistry.

InChI:InChI=1S/C12H13NO4/c14-11(15)10-6-13(7-10)12(16)17-8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,15)

Upstream product

• 36476-78-5 3-azetidinecarboxylic acid 
• 501-53-1 benzyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 757239-60-4 O₁-benzyl-O₃-methylazetidine-1,3-dicarboxylate 

Downstream Products

• 221206-50-4 (3S,3aS,6aR)-3-(6-isopropyl-4-methanesulfonyl-5-oxo-hexahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl)azetidine-1-carboxylic acid benzyl ester 
• 1015005-67-0 C₁₇H₂₃N₃O₅ 
• 618446-42-7 benzyl 3-(hydroxymethyl)azetidine-1-carboxylate 
• 1175529-84-6 benzyl 3-(2-hydroxy-3-(methoxycarbonyl)phenylcarbamoyl)azetidine-1-carboxylate 
• 1228230-77-0 3-(2-iodo-phenylcarbamoyl)-azetidine-1-carboxylic acid benzyl ester 
• 1228230-73-6 azetidine-1,3-dicarboxylic acid 1-benzyl ester 3-(2-oxo-propyl)ester 
• 1236144-51-6 O₁-benzyl-O₃-tert-butylazetidine-1,3-dicarboxylate 
• 1238877-83-2 benzyl 3-[(4-cyclobutylpiperazin-1-yl)carbonyl]azetidine-1-carboxylate 
• 1238876-21-5 benzyl 3-[(4-cyclobutyl-1,4-diazepan-1-yl)carbonyl]azetidine-1-carboxylate 
• 1127402-68-9 benzyl 3-(carbonochloridoyl)azetidine-1-carboxylate 
• 1326281-48-4 benzyl-3-(((3-chloropyrazin-2-yl)methyl)carbamoyl)azetidine-1-carboxylate 
• 1350623-43-6 benzyl 3-[2-(hydroxymethyl)-1,3-thiazol-4-yl]azetidine-1-carboxylate 
• 1207203-37-9 1-((benzyloxy)carbonyl)-3-phenylazetidine-3-carboxylic acid 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

1,3-SUBSTITUTED AZETIDINE PDE10 INHIBITORS

The present invention is directed to substituted azetidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SECONDARY ALCOHOL SUBSITUTED TRIAZOLES AS PDE10 INHIBITORS

The present invention is directed to secondary alcohol substituted triazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.